Inotuzumab Ozogamicin
Treatment for Acute Lymphoid Leukemia
Typical Dosage: 0.8 mg/m² (cycle 1), then 0.5 mg/m² (subsequent cycles) on days 1, 8, 15
Effectiveness
80%
Safety Score
35%
Clinical Trials
50
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
35
DangerousModerateSafe
Treatment Details
Dosage Range
0.8 mg/m² (cycle 1), then 0.5 mg/m² (subsequent cycles) on days 1, 8, 15
Time to Effect
3-6 weeks
Treatment Duration
IV infusion for 21-28 day cycles (2-4 cycles)
Evidence Quality
HIGHConfidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$150,000
Monitoring:$25,000
Side Effect Mgmt:$35,000
Total Annual:$210,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$300,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$262,500
Cost per Remission
$350,000
Comparison vs Standard Chemotherapy
Cost Difference
+$100,000/year
More expensive
QALY Difference
+0.50 QALYs
Better outcomes
Dominance
No dominance
Inotuzumab Ozogamicin Outcomes
for Acute Lymphoid Leukemia
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+80%
Remission Rate
+60%
Common Side Effects
Veno-occlusive disease (VOD)/Sinusoidal obstruction syndrome (SOS)
+11%
Hepatotoxicity
+15%
Myelosuppression
+50%
Fever
+30%
Nausea
+25%
Sources:
Active Clinical Trials
8 active trials recruiting for Inotuzumab Ozogamicin in Acute Lymphoid Leukemia
Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia
NCT06427330RECRUITINGPHASE2
21 participants
INTERVENTIONAL
Tianjin, China
Started: Jul 2, 2024
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
NCT03104491RECRUITINGPHASE1, PHASE2
44 participants
INTERVENTIONAL
Westwood, United States +6 more
Started: Jul 31, 2017
Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy
NCT05456698ACTIVE NOT RECRUITINGPHASE2
31 participants
INTERVENTIONAL
Tianjin, China
Started: Oct 18, 2022
Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease
NCT03441061ACTIVE NOT RECRUITINGPHASE2
40 participants
INTERVENTIONAL
Houston, United States
Started: Feb 15, 2018
A Multi-center Retrospective Study of INO Treating B-ALL
NCT07238907ACTIVE NOT RECRUITING
102 participants
OBSERVATIONAL
Shanghai, China
Started: Jun 1, 2022
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
NCT05748171RECRUITINGPHASE2
100 participants
INTERVENTIONAL
Vienna, Austria +73 more
Started: May 17, 2023
Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
NCT06863259RECRUITINGPHASE1
28 participants
INTERVENTIONAL
Cincinnati, United States
Started: May 21, 2025
Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
NCT06985485RECRUITINGPHASE2
26 participants
INTERVENTIONAL
Suzhou, China
Started: May 17, 2025
Completed Clinical Trials
7 completed trials for Inotuzumab Ozogamicin in Acute Lymphoid Leukemia
InO - A Retrospective Study of UK Patients With Leukaemia
NCT04456959COMPLETED
28 participants
OBSERVATIONAL
Bristol, United Kingdom +3 more
Started: Jan 6, 2020
Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia
NCT01363297COMPLETEDPHASE2
72 participants
INTERVENTIONAL
Duarte, United States +14 more
Started: Aug 1, 2011
A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT05687032COMPLETEDPHASE4
44 participants
INTERVENTIONAL
Beijing, China +15 more
Started: Feb 24, 2023
A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment
NCT05597085COMPLETED
32 participants
OBSERVATIONAL
Gurugram, India +4 more
Started: Mar 8, 2023
A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients
NCT03677596COMPLETEDPHASE4
102 participants
INTERVENTIONAL
Los Angeles, United States +44 more
Started: Jul 1, 2019
CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
NCT01134575COMPLETEDPHASE2
90 participants
INTERVENTIONAL
Houston, United States
Started: Jun 4, 2010
Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML
NCT02311998COMPLETEDPHASE1, PHASE2
22 participants
INTERVENTIONAL
Houston, United States
Started: Apr 16, 2015
Showing 20 of 51 total trials